Lifecome Biochemistry Co.,Ltd. (002868.SZ)
CNY 15.88
(-2.87%)
CNY 15.88
(-2.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -221.81 Million CNY | -80.75% |
| 2022 | -122.72 Million CNY | -364.08% |
| 2021 | -26.44 Million CNY | -161.2% |
| 2020 | 43.2 Million CNY | -24.15% |
| 2019 | 56.96 Million CNY | -23.73% |
| 2018 | 74.68 Million CNY | -13.08% |
| 2017 | 85.92 Million CNY | -6.97% |
| 2016 | 92.36 Million CNY | 18.25% |
| 2015 | 78.1 Million CNY | 148.35% |
| 2014 | 31.44 Million CNY | -4.61% |
| 2013 | 32.97 Million CNY | -23.75% |
| 2012 | 43.24 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -55.73 Million CNY | -77.83% |
| 2024 Q3 | -69.9 Million CNY | -25.42% |
| 2024 Q1 | -31.34 Million CNY | 76.91% |
| 2023 Q4 | -135.73 Million CNY | -244.38% |
| 2023 Q1 | -10.41 Million CNY | 80.93% |
| 2023 FY | -221.81 Million CNY | -80.75% |
| 2023 Q2 | -36.51 Million CNY | -250.58% |
| 2023 Q3 | -39.41 Million CNY | -7.93% |
| 2022 Q3 | -31.43 Million CNY | -13.67% |
| 2022 Q2 | -27.65 Million CNY | -207.14% |
| 2022 Q4 | -54.62 Million CNY | -73.78% |
| 2022 FY | -122.72 Million CNY | -364.08% |
| 2022 Q1 | -9 Million CNY | 55.14% |
| 2021 Q2 | 4.16 Million CNY | 73.34% |
| 2021 Q3 | -12.53 Million CNY | -401.12% |
| 2021 Q4 | -20.07 Million CNY | -60.11% |
| 2021 FY | -26.44 Million CNY | -161.2% |
| 2021 Q1 | 2.4 Million CNY | 8400.4% |
| 2020 Q2 | 22.66 Million CNY | 71.77% |
| 2020 Q1 | 13.19 Million CNY | -39.15% |
| 2020 FY | 43.2 Million CNY | -24.15% |
| 2020 Q4 | -28.93 Thousand CNY | -100.39% |
| 2020 Q3 | 7.37 Million CNY | -67.47% |
| 2019 Q2 | 14.67 Million CNY | 36.27% |
| 2019 Q1 | 10.76 Million CNY | -28.25% |
| 2019 FY | 56.96 Million CNY | -23.73% |
| 2019 Q4 | 21.68 Million CNY | 120.38% |
| 2019 Q3 | 9.83 Million CNY | -32.94% |
| 2018 Q4 | 15 Million CNY | -18.22% |
| 2018 FY | 74.68 Million CNY | -13.08% |
| 2018 Q1 | 18.56 Million CNY | 30.3% |
| 2018 Q2 | 22.76 Million CNY | 22.67% |
| 2018 Q3 | 18.35 Million CNY | -19.39% |
| 2017 Q1 | 26.51 Million CNY | 108.4% |
| 2017 FY | 85.92 Million CNY | -6.97% |
| 2017 Q3 | 24.92 Million CNY | 23.14% |
| 2017 Q4 | 14.24 Million CNY | -42.85% |
| 2017 Q2 | 20.24 Million CNY | -23.67% |
| 2016 Q4 | 12.72 Million CNY | -33.96% |
| 2016 Q3 | 19.26 Million CNY | -34.64% |
| 2016 Q1 | 30.89 Million CNY | 0.0% |
| 2016 Q2 | 29.47 Million CNY | -4.58% |
| 2016 FY | 92.36 Million CNY | 18.25% |
| 2015 FY | 78.1 Million CNY | 148.35% |
| 2014 FY | 31.44 Million CNY | -4.61% |
| 2013 FY | 32.97 Million CNY | -23.75% |
| 2012 FY | 43.24 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Beijing Scitop Bio-tech Co., Ltd. | 93.47 Million CNY | 337.289% |
| Chengdu Kanghua Biological Products Co., Ltd. | 509.21 Million CNY | 143.561% |
| NanHua Bio-medicine Co., Ltd | -28.17 Million CNY | -687.353% |
| Shandong Sito Bio-technology Co., Ltd. | 45.6 Million CNY | 586.4% |
| Porton Pharma Solutions Ltd. | 266.85 Million CNY | 183.122% |
| Zhejiang Wecome Pharmaceutical Company Limited | -8.03 Million CNY | -2659.424% |
| Guangdong VTR Bio-Tech Co., Ltd. | -10.74 Million CNY | -1963.476% |